文献速递胸部CT

病理性IA期肺腺癌术前预后预测:基于三维的实性成分肿瘤比率优于基于二维的实性成分肿瘤比率

Preoperative Prognosis Prediction for Pathological Stage IA Lung Adenocarcinoma: 3D-Based Consolidation Tumor Ratio is Superior to 2D-Based Consolidation Tumor Ratio.
PubMed 文献 · Acad Radiol · 2025-06-06

本研究回顾性纳入980例接受手术的病理性IA期肺腺癌患者,术前薄层CT经人工智能软件三维分割,按不同密度阈值(-300至-150 HU,间隔50 HU)量化实性成分体积并计算三维实性成分肿瘤比率(3D-CTR),与二维实性成分肿瘤比率(2D-CTR)比较术后无复发生存预测效能。结果显示-150 HU为区分实性成分与磨玻璃成分的最佳阈值,3D-CTR预测效能显著优于2D-CTR。

要点

  • 3D-CTR以-150 HU为区分实性与磨玻璃成分的最佳密度阈值。
  • 3D-CTR预测术后复发的AUC 0.867,优于2D-CTR的0.840(P=0.006)。
  • 3D-CTR>0.41组5年无复发生存率68.5%,低于≤0.41组的96.7%。

核心结论

  • 基于-150 HU密度阈值的三维实性成分肿瘤比率较传统二维实性成分肿瘤比率能更准确预测病理性IA期肺腺癌术后复发风险。

研究设计与样本

  • 回顾性队列研究,纳入980例接受手术的病理性IA期肺腺癌患者;术前薄层CT图像经人工智能软件三维分割,以多因素Cox回归选择与预后相关的最佳密度阈值。
  • 以受试者工作特征曲线比较3D-CTR与2D-CTR对术后无复发生存(RFS)的预测效能并确定最佳截断值,采用综合判别改善指数(IDI)评估3D-CTR相对2D-CTR的预测效能提升。

诊断标准与关键数值

  • 3D分析中-150 HU被确定为区分实性成分与磨玻璃密度(GGO)成分的最佳阈值,相应3D-CTR截断值0.41,为RFS的独立危险因素(HR=1.033,P<0.001)。
  • 传统术前因素中2D-CTR(截断值0.54,HR=1.044,P=0.001)与癌胚抗原(CEA)为RFS的独立预后因素。
  • 3D-CTR预测效能显著优于2D-CTR,AUC 0.867 vs 0.840(P=0.006);IDI为0.038(95% CI:0.021-0.055,P<0.001)。
  • Kaplan-Meier分析显示3D-CTR>0.41组5年RFS率68.5%,低于3D-CTR≤0.41组的96.7%(P<0.001)。

临床应用与阅片要点

  • 阅片及术前评估病理性IA期肺腺癌时,可借助人工智能三维分割按-150 HU阈值量化实性成分并计算3D-CTR,作为比2D-CTR更准确的复发风险预测指标。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: The two-dimensional computed tomography measurement of the consolidation tumor ratio (2D-CTR) has limitations in the prognostic evaluation of early-stage lung adenocarcinoma: the measurement is subject to inter-observer variability and lacks spatial information, which undermines its reliability as a prognostic tool. This study aims to investigate the value of the three-dimensional volume-based CTR (3D-CTR) in preoperative prognosis prediction for pathological Stage IA lung adenocarcinoma, and compare its predictive performance with that of 2D-CTR.

METHODS: A retrospective cohort of 980 patients with pathological Stage IA lung adenocarcinoma who underwent surgery was included. Preoperative thin-section CT images were processed using artificial intelligence (AI) software for 3D segmentation. Tumor solid component volume was quantified using different density thresholds (-300 to -150 HU, in 50 HU intervals), and 3D-CTR was calculated. The optimal threshold associated with prognosis was selected using multivariate Cox regression. The predictive performance of 3D-CTR and 2D-CTR for recurrence-free survival (RFS) post-surgery was compared using receiver operating characteristic (ROC) curves, and the best cutoff value was determined. The integrated discrimination improvement (IDI) was utilized to assess the enhancement in predictive efficacy of 3D-CTR relative to 2D-CTR.

RESULTS: Among traditional preoperative factors, 2D-CTR (cutoff value 0.54, HR=1.044, P=0.001) and carcinoembryonic antigen (CEA) were identified as independent prognostic factors for RFS. In 3D analysis, -150 HU was determined as the optimal threshold for distinguishing solid components from ground-glass opacity (GGO) components. The corresponding 3D-CTR (cutoff value 0.41, HR=1.033, P<0.001) was an independent risk factor for RFS. The predictive performance of 3D-CTR was significantly superior to that of 2D-CTR (AUC: 0.867 vs. 0.840, P=0.006), with a substantial enhancement in predictive capacity, as evidenced by an IDI of 0.038 (95% CI: 0.021-0.055, P<0.001). Kaplan-Meier analysis revealed that the 5-year RFS rate for the 3D-CTR >0.41 group was significantly lower than that of the ≤0.41 group (68.5% vs. 96.7%, P<0.001).

CONCLUSION: The 3D-CTR based on a -150 HU density threshold provides a more accurate prediction of postoperative recurrence risk in pathological Stage IA lung adenocarcinoma, demonstrating superior performance compared to traditional 2D-CTR.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Zhao L, Dong H, Chen Y, et al. Preoperative Prognosis Prediction for Pathological Stage IA Lung Adenocarcinoma: 3D-Based Consolidation Tumor Ratio is Superior to 2D-Based Consolidation Tumor Ratio. Acad Radiol. 2025. PMID: 40480938. doi:10.1016/j.acra.2025.05.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。